Another “Awakenings”

haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 2007; 130:1254–1262. 14. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291–301. 15. Fern R, Ransom BR, Waxman SG. Voltage-gated calcium channels in CNS white matter: role in anoxic injury. J Neurophysiol 1995;74:369–377. 16. Imaizumi T, Kocsis JD, Waxman SG. The role of voltage-gated Ca2 channels in anoxic injury of spinal cord white matter. Brain Res 1999;817:84–92. 17. Micu I, Coderre E, Jiang Q, et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature 2006;439:988–992. 18. Ouardouz M, Nikolaeva M, Coderre E, et al. Depolarizationinduced Ca2 release in ischemic spinal cord white matter involves L-type Ca2 channel activation of ryanodine receptors. Neuron 2003;40:53–63. 19. Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na channels and Na -Ca2 exchanger. J Neurosci 1992;12: 430–439. 20. Tekkok SB, Goldberg MP. AMPA/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J Neurosci 2001;21: 4237– 4248. 21. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005;233:3–13. 22. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006;59:478–489. 23. Qi X, Lewin AS, Sun L, et al. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem 2006;281:31950–31962. 24. Stys PK. Axonal degeneration in MS: is it time for neuroprotective strategies? Ann Neurol 2004;55:601–603. 25. Lo AC, Saab CY, Black JA, et al. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 2003;90:3566–3571. 26. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004;55:607–616. 27. Bechtold DA, Miller SJ, Dawson AC, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006;253:1542–1551. 28. Black JA, Liu S, Hains BC, et al. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006;129:3196–3208. 29. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67–70. 30. Smith T, Groom A, Zhu B, et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6: 62–66. 31. Groom AJ, Smith T, Turski L. Multiple sclerosis and glutamate. Ann N Y Acad Sci 2003;993:229–275. 32. Gilgun-Sherki Y, Panet H, Melamed E, et al. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 2003; 989:196–204. 33. Brand-Schieber E, Werner P. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Exp Neurol 2004;189:5–9. 34. Black JA, Liu S, Carrithers M, et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007;62:21–33. 35. Carrithers MD, Dib-Hajj S, Carrithers LM, et al. Expression of the voltage-gated sodium channel Nav1.5 in the macrophage late endosome regulates endosomal acidification. J Immunol 2007;178:7822–7832.